Market revenue in 2024 | USD 1,001.6 million |
Market revenue in 2030 | USD 1,353.7 million |
Growth rate | 4.8% (CAGR from 2025 to 2030) |
Largest segment | Breast cancer |
Fastest growing segment | Breast Cancer |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer |
Key market players worldwide | Abbott Laboratories, Bayer AG, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Qiagen NV, Siemens AG, Sysmex Corp, Becton Dickinson & Co, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based molecular diagnostics market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 21.05% in 2024. Horizon Databook has segmented the Europe oncology based molecular diagnostics market based on breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, blood cancer, kidney cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in prevalence of cancer coupled with growing investments for development of advanced technology is expected to drive the market in this region. However, a new regulation was issued regarding IVD and medical devices in European countries. In 2017, in the EU, a new IVD Regulation (IVDR) and Medical Devices Regulation (MDR) was established.
The changes in the device classification system will encourage all the IVD manufacturers. Currently, most of the IVDs are self-declare devices, where manufacturers are entirely responsible for complying with the guidelines. However, as per the new regulation, around 80% of the devices will need some form of conformity assessment by a notified body.
Class B, C, and D devices will require involvement of notified body. The MDR will be effective from 16 May 2020 and the IVDR from 26 May 2022 and is expected to replace the existing EU medical device directive. The new regulation is estimated to present a more sustainable and robust framework for compliance of molecular diagnostic devices.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe oncology based molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe oncology based molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account